Results 221 to 230 of about 466,117 (305)

Single‐Cell Computational Frameworks for Quantifying BET Bromodomain Inhibitor Resistance and Screening Re‐Sensitizer Drugs in Triple‐Negative Breast Cancer

Advanced Science, EarlyView.
To combat BET inhibitor resistance in triple‐negative breast cancer, we developed two single‐cell computational frameworks. FR20 quantifies resistance by integrating ferroptosis‐related gene signatures, while D‐FR20 screens for potential re‐sensitizers.
Haizhou Liu, Mengqin Yuan, Yini Shang, Jiahao Chen, Fei Hou, Lihong Wang, Wei Jiang   +6 more
wiley   +1 more source

Pathway activity profiling can predict neoadjuvant endocrine therapy response in HR+ HER2- postmenopausal early stage breast cancer. [PDF]

Breast Cancer Res
de Gruil N, de Groot AF, Wesseling-Rozendaal Y, Keizer D, Koekenbier CS, Vermeer S, Cohen D, Heijns JB, Mandigers CMPW, van de Wouw AJ, Cloos-van Balen M, Ropela JA, Oosterkamp HM, van Bekkum ML, Houtsma D, Biezen ED, Liefers GJ, Linn SC, Kroep JR.   +18 more
europepmc   +1 more source

Paving the Way to Elucidate Hg's Role in Tumorigenesis

Advanced Science, EarlyView.
Tumorigenesis can result from diverse environmental carcinogens. Among them, mercury—a lifelong bioaccumulative Group 2B carcinogen—has tumorigenic potential that remains poorly understood due to confounding co‐exposures and limited organ‐specific data.
Shouying Li, Rong Zhong, Zhenyang Yu, Hualing Fu, Jin Chen, Jia Wei, Ningwei Zhao, Le Qu, Tiantian Li, Wenli Tang, Huan Zhong   +10 more
wiley   +1 more source

Survival analysis of adjuvant endocrine therapy in HER2 positive early breast cancer patients with low ER positivity. [PDF]

Breast Cancer Res
Yu HH, Gracia D, Chao TC, Ho CH, Chen HY, Tseng LM, Huang CC.   +6 more
europepmc   +1 more source

Phase Separation of NFIB Suppresses SLC3A2‐Mediated Ferroptosis in Castration‐Resistant Prostate Cancer

Advanced Science, EarlyView.
Castration‐resistant prostate cancer (CRPC) remains sensitive to ferroptosis, but its intrinsic resistance is poorly understood. Here, we identify NFIB as a master suppressor. SIRT7‐mediated NFIB acetylation drives its liquid–liquid phase separation, which promotes SLC3A2 transcription to inhibit ferroptosis.
Qiunuo Li, Danyang Chen, Yongzhen Xia, Yili Long, Nan Huang, Rongna Li, Mengting Shi, Mairehaba Kadier, Huafeng Luo, Xiaohui Chen, Hao Liu, Guanmin Jiang   +11 more
wiley   +1 more source

Pathological Complete Response after Robot-Assisted Pulmonary Resection Following CDK4/6 Inhibitor-Combined Endocrine Therapy for Endobronchial Oligometastatic Breast Cancer: A Case Report. [PDF]

Surg Case Rep
Nitahara H, Goto W, Nishikawa M, Watanabe C, Takada K, Tauchi Y, Ogisawa K, Kinoshita H, Morisaki T, Kohashi K, Kashiwagi S.   +10 more
europepmc   +1 more source

Atrophic Skeletal Muscle‐Derived Extracellular Vesicles Transfer miR‐125a‐5p to Inhibit Bone Formation in Osteoporosis during Aging

Advanced Science, EarlyView.
A muscle‐bone endocrine pathway in aging is revealed in which extracellular vesicles released from atrophic skeletal muscle (Aged‐SKM‐EVs) inhibit bone formation. These EVs deliver miR‐125a‐5p to osteoblasts, thereby suppressing the SIRT7‐Sp7 signaling axis and osteogenic differentiation.
Xiaoyan Shao, Pan Zhang, Zhidan Fan, Jiaquan Lin, Xiang Chen, Na Liu, Wang Gong, Yi He, Yining Zhou, Tianshu Shi, Yong Shi, Yuze Ma, Wentian Gao, Haosheng Wang, Depeng Fang, Chengzhi Wang, Wenshu Wu, Wenjin Yan, Jianghui Qin, Dongyang Chen, Haiguo Yu, Qing Jiang, Baosheng Guo   +22 more
wiley   +1 more source

Exploring the Impact of Initiating Endocrine Therapy on Metabolic Health in Early Breast Cancer: Protocol for the Prospective Follow-Up EMETA-Study.

JMIR Res Protoc
Nissen L, Busk Holm J, Borgquist S.
europepmc   +1 more source

Patient-reported tolerance of 90 days of preoperative endocrine therapy: results from the preoperative window of endocrine therapy to inform radiation therapy decisions trial. [PDF]

Oncologist
Millard T, Turkheimer LM, Schlefman J, Petroni GR, Brighton D, Showalter SL.   +5 more
europepmc   +1 more source

Understanding and Overcoming Antibody‐Drug Conjugate Resistance: Biological Mechanisms and Emerging Analytical Frameworks in Breast Cancer

Advanced Science, EarlyView.
Antibody–drug conjugates (ADCs) transform breast cancer therapy, yet resistance limits their durability. Emerging evidence reveals that ADC failure is not solely tumor‐intrinsic but shaped by dynamic tumor–microenvironment interactions that alter drug delivery, processing, and response.
Minji Seo, Jangsoon Lee, Naoto T. Ueno
wiley   +1 more source